Dear Editor,The COVID-19 pandemic has driven great interest in the therapeutic potential of repurposed drugs with well-established benefits and safety profiles(toxicity,bioavailability,etc.),many of which act via sign...Dear Editor,The COVID-19 pandemic has driven great interest in the therapeutic potential of repurposed drugs with well-established benefits and safety profiles(toxicity,bioavailability,etc.),many of which act via signal transduction pathways.One category of such drugs is those that reduce acid production in gastroenterological contexts.展开更多
基金This work was supported by TRR295,KF0339,and DFG PR1562/1-1Portions of this work were also supported by the University of Virginia School of Data Science and by NSF CAREER award MCB-1350957.
文摘Dear Editor,The COVID-19 pandemic has driven great interest in the therapeutic potential of repurposed drugs with well-established benefits and safety profiles(toxicity,bioavailability,etc.),many of which act via signal transduction pathways.One category of such drugs is those that reduce acid production in gastroenterological contexts.
